1. Home
  2. CYH vs OVID Comparison

CYH vs OVID Comparison

Compare CYH & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Community Health Systems Inc.

CYH

Community Health Systems Inc.

SELL

Current Price

$2.02

Market Cap

411.7M

Sector

Health Care

ML Signal

SELL

Logo Ovid Therapeutics Inc.

OVID

Ovid Therapeutics Inc.

SELL

Current Price

$2.22

Market Cap

479.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CYH
OVID
Founded
1985
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
411.7M
479.4M
IPO Year
2000
2017

Fundamental Metrics

Financial Performance
Metric
CYH
OVID
Price
$2.02
$2.22
Analyst Decision
Hold
Strong Buy
Analyst Count
10
13
Target Price
$2.51
★ $6.15
AVG Volume (30 Days)
2.2M
★ 2.5M
Earning Date
10-28-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 196.67
3.90
EPS
N/A
★ N/A
Revenue
★ $12,485,000,000.00
$7,252,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 1181.27
52 Week Low
$2.04
$1.21
52 Week High
$3.92
$3.11

Technical Indicators

Market Signals
Indicator
CYH
OVID
Relative Strength Index (RSI) 33.59 39.29
Support Level $2.04 $2.12
Resistance Level $3.04 $2.67
Average True Range (ATR) 0.18 0.25
MACD -0.01 -0.03
Stochastic Oscillator 3.06 1.61

Price Performance

Historical Comparison
CYH
OVID

About CYH Community Health Systems Inc.

Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.

About OVID Ovid Therapeutics Inc.

Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

Share on Social Networks: